Mario Murguia-Perez

Prof. Dr. Mario Murguia-Perez

Pathology, UMAE Hospital de Especialidades N° 1 CMN Bajío, IMSS, León, Mexico
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2016 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
BMBirzabith Mendoza‐Novelo
Birzabith Mendoza‐Novelo
LCLaura E. Castellano
Laura E. Castellano
RPRuth G. Padilla‐Miranda
Ruth G. Padilla‐Miranda
MLMaría C. Lona‐Ramos
María C. Lona‐Ramos
PCPatricia Cuéllar‐Mata
Patricia Cuéllar‐Mata
EÁEva E. Ávila
Eva E. Ávila

Verified
Journal Article
Open access
PDF file
LBLeticia Bornstein-Quevedo
Leticia Bornstein-Quevedo
JAJazmín de Anda-González
Jazmín de Anda-González
CLCesar Octavio Lara-Torres
Cesar Octavio Lara-Torres
JFJuan Pablo Flores-Gutiérrez
Juan Pablo Flores-Gutiérrez
RDRita Dorantes-Heredia
Rita Dorantes-Heredia
CAClaudia Arce-Salinas
Claudia Arce-Salinas
The article discusses the importance of accurately distinguishing HER2-low from HER2-negative breast cancer, as novel ADCs have demonstrated activity in a large population of patients with HER2-low-expressing BC. While current guidelines recommend a dichotomous classification of HER2 as either positive or negative, the emergence of the HER2-low concept calls for standardization of HER2 testing in breast cancer, using currently available assays to better discriminate HER2 levels. This review covers the evolution and latest updates of the ASCO/CAP guidelines relevant to this important biomarker in breast cancer, including still-evolving concepts such as HER2 low, HER2 heterogeneity, and HER2 evolution. Our group presents the latest Mexican recommendations for HER2 status evaluation in breast cancer, considering the ASCO/CAP guidelines and introducing the HER2-low concept. In the era of personalized medicine, accurate HER2 status assessment remains one of the most important biomarkers in breast cancer, and the commitment of Mexican pathologists to theragnostic biomarker quality is crucial for providing the most efficient care in oncology.

10 January 2022 in Frontiers in Medicine
Verified
Journal Article
Open access
YGYunuén I. García-Mendoza
Yunuén I. García-Mendoza
Mario Murguia-PerezMario Murguia-Perez
Mario Murguia-Perez
AGAldo I. Galván-Linares
Aldo I. Galván-Linares
SMSaulo Mendoza-Ramírez
Saulo Mendoza-Ramírez
NGNorma L. García-Salinas
Norma L. García-Salinas
GCGuillermo E. Corredor-Alonso
Guillermo E. Corredor-Alonso
A 46- year-old woman presented a uterine adenosarcoma originating in the lower uterine segment. The diagnosis was made in an endometrial biopsy and confirmed in the pathological examination of the complete surgical specimen, both identifying heterologous malignant elements. In addition, complementary immunohistochemical studies were performed. We reviewed the literature, illustrating the clinical and morphological characteristics and the differential diagnoses to be evaluated.

12 August 2024 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
BMBlanca Olivia Murillo-Ortiz
Blanca Olivia Murillo-Ortiz
KGKenia García-Corrales
Kenia García-Corrales
SMSandra Martínez-Garza
Sandra Martínez-Garza
MRMarcos Javier Romero-Vázquez
Marcos Javier Romero-Vázquez
EAEduardo Agustín-Godínez
Eduardo Agustín-Godínez
Mario Murguia-PerezMario Murguia-Perez
Mario Murguia-Perez
Background: Breast cancer shows significant clinical, morphologic, and molecular variation. Telomeres are nucleoprotein complexes composed of hexanucleotide repeat DNA sequence, TTAGGG, and numerous telomere-associated proteins. The maintenance of telomere length is carried out by a ribonucleoprotein called telomerase, which consists of two main components: a catalytic subunit called hTERT (human telomerase reverse transcriptase) and an RNA template called hTR (human telomerase RNA). The importance of evaluating hTERT expression lies in its potential therapeutic application, being an attractive target due to its almost non-existent expression in normal somatic cells. It is also expected that the anti-neoplastic effect would appear earlier in neoplastic cells with shorter telomeres. Additionally, a significant relationship has been observed between Her2-Neu overexpression and Her2-Neu positivity, which could suggest new combined therapies.The aim of this study was to detect the expression of hTERT, estrogen receptor (ER), progesterone receptor (PR), and HER2-Neu in neoplastic breast tissue embedded in paraffin before treatment and to investigate the relationship between them and with baseline and post-treatment telomere length, as well as with various clinicopathological parameters.Materials and methods: A cross-sectional-correlational, 21 women diagnosed with breast cancer at the Oncology Service of the High Specialty Medical Unit No. 1 of Bajio of the Mexican Institute of Social Security. The study complies with the Helsinki Declaration and was approved by the Institutional Ethical Committee of the Mexican Institute of Social Security (R-2019-1001-127). A peripheral blood sample was obtained before oncological treatment and at the end of oncological treatment for the measurement of telomere length by extracting DNA from leukocytes, was performed by the quantitative polymerase chain reaction (PCR) method described by Cawthon. Tumor samples were collected from each patient at the oncology department for immunohistochemical determination of biomarker expression (ER, PR, Her2/neu) and hTERT.Results: Of the 21 cases included in the study, the median age was 57.57 years. Eighteen cases were classified as invasive ductal carcinoma NOS (85.71%), 10 were histologic grade 2 (47.61%), 16 cases were hormone receptor positive (76.19%), 7 were Her2Neu positive (33.33%), and only 2 cases were triple negative (9.52%). Positive hTERT expression was detected in 11 cases (52.38%) and was negative in the remaining cases. A significant association was identified between hTERT-positive cases and Her2-Neu positive cases (p = 0.04). Baseline and post-treatment telomere lengths showed a significant difference using the non-parametric Wilcoxon t-test (p = 0.002). In hTERT-positive cases, there was significant telomere shortening at the end of oncological treatment (6.14 ± 1.54 vs. 4.75 ± 1.96 Kb, p = 0.007).Conclusion: Positive hTERT immunostaining cases were associated with poor prognostic factors, such as Her2-Neu overexpression and post-treatment telomere shortening. In the future, hTERT immunostaining could be used to select patients for therapies with antagonistic effects on hTERT, as well as in the selection of more appropriate chemotherapy regimens for patients who express it.

10 December 2018 in Journal of Biomaterials Applications
Verified
Journal Article
Closed access
APAarón de Jesus Palacios-Rodríguez
Aarón de Jesus Palacios-Rodríguez
MFMauricio Flores-Moreno
Mauricio Flores-Moreno
LCLaura Edith Castellano
Laura Edith Castellano
RCRamón Carriles
Ramón Carriles
IQIraís Quintero-Ortega
Iraís Quintero-Ortega
BMBirzabith Mendoza-Novelo
Birzabith Mendoza-Novelo
The stability and bioactivity of biologic implants rely mainly on the control of the crosslinking process of collagen. However, the most common methods have no control on the crosslinking degree producing it excessively. This study outlines the role of crosslinking of collagen-based implants with oligourethane on the host response following reconstruction of a rat full-thickness abdominal wall defect. We decellularized and crosslinked bovine pericardial tissue to achieve two crosslinking degrees. For the decellularized implants, named as non-crosslinked (N-CL), the collagen-amines were 0.42 ± 0.02 mmol/mg. Crosslinking by the oligourethane reduced the primary amine concentration to 0.28 ± 0.01 and 0.19 ± 0.01 mmol/mg; these values were classified as low (∼30%, L-CL) and medium crosslinking (∼50%, M-CL), respectively. By imaging the implants using second harmonic generation microscopy, we observed undulated bundles of collagen fibers organized in multi-directed layers localized in N-CL and L-CL samples. Post-implantation, a negligible change in the organization of collagen fibers in the crosslinked implants was observed, suggesting that the in vivo biodegradation was delayed. An enlargement of the implant area was also observed, without rupture, in all three (N-CL, L-CL, M-CL) materials, whereas adhesion to the omentum, but not to the bowel, was observed. The number of blood vessels after 90-day implantation in N-CL and L-CL was 13 ± 1 and 12 ± 1 per field, respectively, while the number significantly decreased to 2 ± 1 in M-CL. The results suggest that the controlled degree of crosslinking in oligourethane-modified biologic implants can be used as a strategy to balance biodegradation and remodeling in surgical repair of soft tissues.

Verified
Journal Article
Open access
PDF file
MCMarlid Cruz-Ramos
Marlid Cruz-Ramos
SCSara Aileen Cabrera-Nieto
Sara Aileen Cabrera-Nieto
Mario Murguia-PerezMario Murguia-Perez
Mario Murguia-Perez
FEFernanda Sarahí Fajardo Espinoza
Fernanda Sarahí Fajardo Espinoza
Resistance to systemic therapies in sarcomas poses a significant challenge to improving clinical outcomes. Recent research has concentrated on the tumor microenvironment’s role in sarcoma progression and treatment resistance. This microenvironment comprises a variety of cell types and signaling molecules that influence tumor behavior, including proliferation, metastasis, and resistance to therapy. Adenosine, abundant in the tumor microenvironment, has been implicated in promoting immunosuppression and chemoresistance. Targeting adenosine receptors and associated pathways offers a novel approach to enhancing immune responses against tumors, potentially improving immunotherapy outcomes in cancers, including sarcomas. Manipulating adenosine signaling also shows promise in overcoming chemotherapy resistance in these tumors. Clinical trials investigating adenosine receptor antagonists in sarcomas have fueled interest in this pathway for sarcoma treatment. Ultimately, a comprehensive understanding of the tumor and vascular microenvironments, as well as the adenosine pathway, may open new avenues for improving treatment outcomes and overcoming resistance in sarcoma. Further studies and clinical trials are crucial to validate these findings and optimize therapeutic strategies, particularly for osteosarcoma. This study provides a literature review exploring the potential role of the adenosine pathway in sarcomas.